Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Latest Articles
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • Topics
    • Applied and Environmental Science
    • Clinical Science and Epidemiology
    • Ecological and Evolutionary Science
    • Host-Microbe Biology
    • Molecular Biology and Physiology
    • Therapeutics and Prevention
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About mBio
    • Editor in Chief
    • Board of Editors
    • AAM Fellows
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
mBio
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Latest Articles
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • Topics
    • Applied and Environmental Science
    • Clinical Science and Epidemiology
    • Ecological and Evolutionary Science
    • Host-Microbe Biology
    • Molecular Biology and Physiology
    • Therapeutics and Prevention
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About mBio
    • Editor in Chief
    • Board of Editors
    • AAM Fellows
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
Research Article | Host-Microbe Biology

Direct Intracellular Visualization of Ebola Virus-Receptor Interaction by In Situ Proximity Ligation

Eva Mittler, Tanwee Alkutkar, Rohit K. Jangra, Kartik Chandran
Carolyn B. Coyne, Editor
Eva Mittler
aAlbert Einstein College of Medicine, Department of Microbiology & Immunology, Bronx, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eva Mittler
Tanwee Alkutkar
aAlbert Einstein College of Medicine, Department of Microbiology & Immunology, Bronx, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rohit K. Jangra
aAlbert Einstein College of Medicine, Department of Microbiology & Immunology, Bronx, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rohit K. Jangra
Kartik Chandran
aAlbert Einstein College of Medicine, Department of Microbiology & Immunology, Bronx, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kartik Chandran
Carolyn B. Coyne
University of Pittsburgh School of Medicine
Roles: Editor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/mBio.03100-20
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Supplemental Material
  • FIG 1
    • Open in new tab
    • Download powerpoint
    FIG 1

    Development of an EBOV GP-NPC1 binding assay in intact cells by in situ proximity ligation. (A) VSV mNG-P particles bearing EBOV GP were internalized into U2OS cells ectopically expressing NPC1-eBFP2 for 60 min. Cells were fixed, permeabilized, and subjected to proximity ligation assay (PLA) using GPCL- and NPC1-specific antibodies (MR72/MAb-548). During amplification, resulting PLA products were labeled with a detector oligonucleotide conjugated with a red fluorophore. White arrowheads, VSV/NPC1 colocalization; red arrowheads, VSV/NPC1/PLA colocalization. (B) VSVs bearing EBOV GP were endocytosed into U2OS cells as described in panel A, fixed at the indicated time points, and subjected to PLA. VSV-positive compartments (VSV+) were enumerated; the percentages of compartments also positive for NPC1 (VSV+/NPC1+) or NPC1 plus PLA (VSV+/NPC1+/PLA+) were determined. Averages of pooled cells out of two independent experiments are shown (n ≥ 30 per time point).

  • FIG 2
    • Open in new tab
    • Download powerpoint
    FIG 2

    Proximity ligation is sensitive to perturbations in the GPCL-NPC1 domain C interface. (A) VSV mNG-P particles bearing EBOV GP or EBOV GPT83M/K114E/K115E were internalized into U2OSNPC1-eBFP2 cells for 60 min followed by cell fixation, permeabilization, and PLA. Cells were analyzed by fluorescence microscopy; data points represent the percentage of VSV+/NPC1+/PLA+ compartments per individual cell; bars depict the pooled averages and standard deviations (± SD) for all cells from two independent experiments (n ≥ 40). An unpaired two-tailed t test was used to compare VSV+/NPC1+/PLA+ compartments of cells infected by VSV bearing either EBOV GP or EBOV GPT83M/K114E/K115E (****, P < 0.0001). Group means calculated from the percentage of VSV+/NPC1+/PLA+ vesicles were compared by Cohen’s d effect size (d > 1.3). (B) U2OSNPC1-eBFP2 cells were preincubated with the inhibitor 3.47 (1 μM) for 60 min at 37°C followed by VSV mNG-P EBOV GP uptake for 60 min and PLA. Data points were acquired and analyzed as described in panel A. (C) After preincubation of U2OSNPC1-eBFP2 and wild-type U2OS cells with increasing 3.47 concentrations, cells were infected with VSV mNG-P EBOV GP for 16 h. Infection was measured by automated counting of mNG+ cells and normalized to infection obtained in the absence of 3.47. Averages ± SD for six technical replicates pooled from two independent experiments are displayed. Data were subjected to nonlinear regression analysis to derive 3.47 concentration at half-maximal inhibition of infection (IC50 ± 95% confidence intervals for nonlinear curve fit).

  • FIG 3
    • Open in new tab
    • Download powerpoint
    FIG 3

    Detection of GPCL-NPC1 binding by PLA requires endosomal cleavage of GP. (A) VSV mNG-P particles bearing EBOV GP were incubated with either U2OSNPC1-eBFP2 cells pretreated with E-64d (100 mM for 6 h at 37°C) (left) or U2OS CatB/L-KO cells ectopically overexpressing Flag-tagged NPC1 (right). Cells were fixed following virus incubation (1 h at 37°C), permeabilized, and subjected to PLA. Data points represent the percentage of VSV+/NPC1+/PLA+ compartments per individual cell; bars depict the average ± SD for all data points pooled from two independent experiments (n ≥ 30). Points with reduced transparency represent values outside the 10th to 90th percentiles. An unpaired two-tailed t test was used to compare VSV+/NPC1+/PLA+ compartments of wild-type cells with either inhibitor-treated (left) or KO (right) cells infected by EBOV GP-decorated VSV (****, P < 0.0001). Group means calculated from the percentage of VSV+/NPC1+/PLA+ vesicles were compared by Cohen’s d effect size. (B) Cells described in panel A were exposed to VSV mNG-P EBOV GP uptake for 1 h at 37°C. After fixation, viral particles, NPC1, and GPCL were visualized by fluorescence microscopy. Representative images from two independent experiments are shown. (C) VSV mNG-P particles bearing EBOV GP were treated in vitro with thermolysin (THL) or cathepsin L (CatL), respectively. Viral particles were taken up into U2OSNPC1-eBFP2 cells followed by fixing of the cells and subjecting them to PLA. Data points represent the percentage of VSV+/NPC1+/PLA+ compartments per individual cell; bars depict the average ± SD for all data points pooled from two independent experiments (n ≥ 25). To compare VSV+/NPC1+/PLA+ compartments of cells which endocytosed VSV studded with either uncleaved or THL/CatL-cleaved GP, an unpaired two-tailed t test was used (****, P < 0.0001). Cohen’s d effect size was used to compare the group means calculated from the percentages of VSV+/NPC1+/PLA+ vesicles (d > 1.3). (D) U2OSNPC1-eBFP2 cells were (not) preincubated with E-64d (as described in panel A), and VSV mNG-P particles bearing EBOV GP were treated in vitro with THL. Following virus internalization into U2OSNPC1-eBFP2, cells were fixed and subjected to PLA. Data points represent the percentage of VSV+/NPC1+/PLA+ compartments per individual cell; bars depict the average ± SD for all data points pooled from two independent experiments (n ≥ 25). Points with reduced transparency represent values outside the 10th to 90th percentiles. To compare VSV+/NPC1+/PLA+ compartments of E-64d-treated cells with those of untreated cells which endocytosed VSV studded with either uncleaved or THL-cleaved GP, an unpaired two-tailed t test was used (**, P < 0.01; ***, P < 0.001; ****, P < 0.0001). Cohen’s d effect size was used to compare the group means calculated from the percentages of VSV+/NPC1+/PLA+ vesicles.

  • FIG 4
    • Open in new tab
    • Download powerpoint
    FIG 4

    In situ proximity ligation decouples GPCL-NPC1 interaction from post-binding entry steps. (A) VSV mNG-P particles bearing EBOV GP or EBOV GPL529A/I544A were internalized into U2OSNPC1-eBFP2 cells for 60 min followed by PLA. Data points represent the percentage of triple-positive compartments per individual cell; bars depict the average ± SD for all data points pooled from two independent experiments (n ≥ 37). Data analyses included an unpaired two-tailed t test to compare VSV+/NPC1+/PLA+ vesicles of cells which internalized VSV decorated with wild-type or mutant GP (ns, P > 0.05). Cohen’s d effect size was used to compare the group means calculated from the percentages of VSV+/NPC1+/PLA+ compartments. (B) ADI-15946 was incubated with VSV EBOV GP particles and exposed to U2OSNPC1-eBFP2 (right). After virus uptake for 1 h at 37°C, cells were fixed, and viral particles, NPC1, and bound antibodies were visualized by fluorescence microscopy. Representative images from two independent experiments are shown. Virions were preincubated with increasing amounts of KZ52, mAb100, ADI-15946, or ADI-16061 and then exposed to U2OSNPC1-eBFP2 cells for 16 h at 37°C (left). The number of infected cells was determined by automated counting of mNG+ cells and normalized to infection obtained in the absence of antibodies. Averages ± SD for six technical replicates pooled from two independent experiments are shown. (C) VSV mNG-P EBOV GP virions were complexed with KZ52, mAb100, ADI-15946, or ADI-16061 (50 μg/ml and 100 μg/ml) for 1 h at room temperature. Following internalization into U2OSNPC1-eBFP2, cells were fixed and subjected to in situ PLA. Data points represent the percentage of VSV+/NPC1+/PLA+ compartments per individual cell; bars show the average ± SD for all data points pooled from two independent experiments (n ≥ 22). VSV+/NPC1+/PLA+ vesicles were analyzed by unpaired two-tailed t test (ns, P > 0.05; *, P < 0.05; **, P < 0.01; ****, P < 0.0001) comparing cells which were exposed to virion-antibody complexes to cells exposed to untreated virus. Group means calculated from the percentage of VSV+/NPC1+/PLA+ vesicles were also compared by Cohen’s d effect size.

  • FIG 5
    • Open in new tab
    • Download powerpoint
    FIG 5

    Small-molecule inhibitor-mediated selective interference of GP-NPC1 binding delineated by in situ PLA. (A) U2OSNPC1-eBFP2 cells were preincubated with increasing concentrations of amiodarone, bepridil, clomifene, sertraline, toremifene, and U18666A, respectively, before exposure to VSV mNG-P EBOV GP for 16 h at 37°C. Infection was measured by automated counting of mNG+ cells and normalized to infection obtained in the presence of vehicle only. Averages ± SD for 9 to 18 technical replicates pooled from 3 to 6 independent experiments are displayed. (B) U2OSNPC1-eBFP2 cells were incubated with amiodarone, bepridil, clomifene, and sertraline, respectively (2 μM or 5 μM, 1 h at 37°C), toremifene (2 μM or 10 μM, 1 h at 37°C), or U18666A (10 μM, 2 h at 37°C), followed by VSV mNG-P EBOV GP uptake for 1 h. Cells were subjected to in situ PLA and analyzed by fluorescence microscopy. The percentage of triple-positive VSV+/NPC1+/PLA+ compartments per individual cell is represented by data points; bars show the average ± SD for all data points pooled from two independent experiments (n ≥ 20). VSV+/NPC1+/PLA+ vesicles were analyzed by unpaired two-tailed t test (ns, P > 0.05; *, P < 0.05; ****, P < 0.0001) comparing inhibitor-exposed to untreated cells. Group means calculated from the percentage of VSV+/NPC1+/PLA+ compartments were also compared by Cohen’s d effect size. (C) Table summarizing results from panel B and Fig. S6 in the supplemental material. Data for “virus trafficking” can be found in Fig. S6B, data for “GPCL-NPC1 binding” are shown in panel B, data for “NPC1 detection” and “GPCL detection” are not shown, exemplary images for “cholesterol accumulation” are depicted in Fig. S6C, top, and exemplary images for “NPC1+ LE morphology” are shown in Fig. S6C, bottom.

Supplemental Material

  • Figures
  • FIG S1

    PLA requires the presence of both detecting antibodies and VSV internalization. VSV mNG-P particles bearing EBOV GP were exposed to U2OSNPC1-eBFP2 cells for 1 h at 37°C or, to inhibit endocytosis, at 4°C. Cells were fixed, permeabilized, and subjected to in situ PLA using GPCL-specific (MR72) or NPC1 domain C-specific (MAb-548) antibodies only or a combination of both. The percentage of VSV+/NPC1+/PLA+ compartments per cell was determined by fluorescence microscopy and presented here by individual data points. Graphic bars show the average ± SD for all data points pooled from one to two independent experiments (n ≥ 10). Download FIG S1, TIF file, 2.5 MB.

    Copyright © 2021 Mittler et al.

    This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

  • FIG S2

    GPCL-NPC1 interface formation is required for in situ PLA. (A) VSV particles bearing EBOV GP or EBOV GPT83M/K114E/K115E were exposed to U2OSNPC1-eBFP2 cells for 1 h at 37°C. After fixation, viral particles, NPC1, and GPCL were visualized by fluorescence microscopy. Representative images from two independent experiments are shown. (B) Virions bearing EBOV GP or EBOV GPT83M/K114E/K115E normalized for the VSV matrix protein M (data not shown) were used to infect U2OSNPC1-eBFP2 cells. Infection was measured by manual counting of mNG+ cells and normalized to infection with VSV mNG-P decorated with wild-type GP. Averages ± SD for four technical replicates pooled from two independent experiments are presented. (C) After incubation of U2OSNPC1-eBFP2 cells with 3.47 (1 μM, 1 h at 37°C), cells were either directly fixed or exposed to VSV mNG-P EBOV GP for 1 h at 37°C prior to fixation. NPC1 was detected by MAb-548 (top), and GPCL was detected by MR72 (bottom). Representative images of fluorescence microscopy from two independent experiments are shown. Download FIG S2, TIF file, 2.1 MB.

    Copyright © 2021 Mittler et al.

    This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

  • FIG S3

    Endosomal protease activity is essential for EBOV GP-mediated particle infectivity. (A) U2OSNPC1-eBFP2 cells were treated with E-64d (100 mM, 6 h at 37°C) followed by infection with VSV bearing EBOV GP. The number of infected cells was determined by manual counting of mNG+ cells and normalized to infection obtained in the presence of vehicle only. Averages ± SD for four technical replicates pooled from two independent experiments are presented. (B) After in vitro treatment of VSV mNG-P EBOV GP particles with thermolysin (THL) or cathepsin L (CatL), virions were normalized by a quantitative Western blot assay detecting VSV M and exposed to U2OSNPC1-eBFP2 cells. The number of infected cells was determined by manual counting of mNG+ cells and normalized to infection obtained with untreated VSV mNG-P EBOV GP. Averages ± SD for four technical replicates pooled from two independent experiments are presented. Download FIG S3, TIF file, 0.2 MB.

    Copyright © 2021 Mittler et al.

    This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

  • FIG S4

    Characterization of CRISPR/Cas9-generated U2OS CatB/L-KO cells. (A) Alignment of the wild-type Cat L and B gene sequences with alleles in the CatB/L-KO cell clone. The guide RNA (gRNA) target sequence is depicted in red; the PAM sequence is depicted in blue. (B) CatB and CatL activities in U2OS cell extracts were measured by fluorogenic peptide turnover. As a control, the proteolytic activity in U2OS CatL- or CatB-KO cells and U2OS cells, which were pretreated for 20 min with 20 μM E-64d, was also determined. Averages ± SD for six technical replicates pooled from two independent experiments are presented. (C) Susceptibility of U2OS CatB/L-KO cells and U2OS CatB/L-KO cells ectopically overexpressing Flag-tagged NPC1 to EBOV GP and VSV G-mediated VSV infection. The number of infected cells was determined by manual counting of eGFP+ or mNG+ cells and normalized to infection obtained with wild-type U2OS cells. Download FIG S4, TIF file, 0.5 MB.

    Copyright © 2021 Mittler et al.

    This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

  • FIG S5

    In situ PLA allows decoupling of GP-NPC1 binding from post-NPC1 binding steps. (A) VSV mNG-P particles studded with EBOV GP or EBOV GPL529A/I544A were internalized into U2OSNPC1-eBFP2 cells for 1 h. Following fixation, viral particles, NPC1, and GPCL were visualized by fluorescence microscopy. Representative images from two independent experiments are shown. (B) Virions bearing EBOV GP were first complexed with KZ52, mAb100, or ADI-16061 antibodies (50 μg/ml) for 1 h at room temperature, and then virus-antibody complexes were internalized into U2OSNPC1-eBFP2 cells. By fluorescence microscopy, viral particles, NPC1, and bound antibodies were visualized. (C) Samples were generated as described in panel B, and viral particles, NPC1, and GPCL (via MR72) were visualized by fluorescence microscopy. Download FIG S5, TIF file, 1.3 MB.

    Copyright © 2021 Mittler et al.

    This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

  • FIG S6

    Small-molecule inhibitors interfere with cell susceptibility to infection, virus trafficking, as well as NPC1 distribution and function. (A) Wild-type U2OS or U2OSNPC1-eBFP2 cells were preincubated with increasing amounts of indicated inhibitors and then exposed to VSV decorated with EBOV GP for 16 h at 37°C in presence of the inhibitors. The number of infected cells was determined by automated counting of eGFP+ cells and normalized to infection obtained in the absence of inhibitors. Averages for six technical replicates pooled from two independent experiments are shown. (B) As outlined in Fig. 5B, U2OSNPC1-eBFP2 cells were incubated with amiodarone, bepridil, clomifene, toremifene, sertraline, and U18666A, respectively, followed by VSV mNG-P EBOV GP uptake for 1 h. Cells were subjected to in situ PLA and analyzed by fluorescence microscopy. The percentage of double-positive VSV+/NPC1+ compartments per individual cell is represented by data points; bars show the average ± SD for all data points pooled from two independent experiments (n ≥ 20). VSV+/NPC1+ vesicles were analyzed by unpaired two-tailed t-test (ns, P > 0.05; *, P < 0.05; ***, P < 0.001; ****, P < 0.0001) comparing inhibitor-exposed to vehicle-treated cells. (C) U2OSNPC1-eBFP2 cells were incubated with U18666A (10 μM), amiodarone (5 μM), bepridil (5 μM), clomifene (5 μM), sertraline (5 μM), toremifene (10μ M), or DMSO carrier for 16 h at 37°C, followed by detection of NPC1 by MAb-548 (bottom) or NPC1 detection followed by filipin staining highlighting cholesterol accumulations (top) and analyzed by fluorescence microscopy. Download FIG S6, TIF file, 1.5 MB.

    Copyright © 2021 Mittler et al.

    This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

PreviousNext
Back to top
Download PDF
Citation Tools
Direct Intracellular Visualization of Ebola Virus-Receptor Interaction by In Situ Proximity Ligation
Eva Mittler, Tanwee Alkutkar, Rohit K. Jangra, Kartik Chandran
mBio Jan 2021, 12 (1) e03100-20; DOI: 10.1128/mBio.03100-20

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this mBio article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Direct Intracellular Visualization of Ebola Virus-Receptor Interaction by In Situ Proximity Ligation
(Your Name) has forwarded a page to you from mBio
(Your Name) thought you would be interested in this article in mBio.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Direct Intracellular Visualization of Ebola Virus-Receptor Interaction by In Situ Proximity Ligation
Eva Mittler, Tanwee Alkutkar, Rohit K. Jangra, Kartik Chandran
mBio Jan 2021, 12 (1) e03100-20; DOI: 10.1128/mBio.03100-20
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • RESULTS
    • DISCUSSION
    • MATERIALS AND METHODS
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

NPC1
Ebola virus
glycoprotein
inhibitors
proximity ligation
virus entry

Related Articles

Cited By...

About

  • About mBio
  • Editor in Chief
  • Board of Editors
  • AAM Fellows
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Author Warranty
  • Article Types
  • Ethics
  • Contact Us

Follow #mBio

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Online ISSN: 2150-7511